Eptifibatide

Product overview
Catalog Number
PPH08-0433
Sequence
[Mpa-Har-Gly-Asp-Trp-Pro-Cys]-NH2
Target
Originally derived from a protein obtained from the venom of Southeastern Pygmy Rattlesnake, this cyclic heptapeptide is an anti-platelet which binds to glycoprotein IIb-IIIa.
Description
Eptifibatide binds to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets and inhibits platelet aggregation. Eptifibatide is a cyclic peptide derived from a protein discovered in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarus barbouri). Eptifibatide belongs to the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Synthetic Eptifibatide is a 6 amino acid peptide having a MW of 832.5 Dalton the following sequence Mpr-Har-Gly-Asp-Trp-Pro-Cys-NH2. Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein (P22827) found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The drug is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody abciximab and the non-peptide tirofiban entered the global market.
Category
Product Properties
Quantity

1mg, 5mg

Storage

Shipped at 4°C. Store at -20°C for one year.

Purity

> 95%

Source

Synthetic

Forma appearance

Lyophilized powder

  • For research use only
  • Not for use in diagnostic procedures

32,00141,00 Tax excluded

Contact us to request price here
Register to buy peptides
Contact us